Jiangxi Biology Passes HKEX Hearing, World’s Largest Provider of Human Tetanus Antitoxin

NewTimeSpace · 2026/06/08 13:18 · By Mingzhe Sun

NewTimeSpace News: Jiangxi Institute of Biological Products Inc. passed the hearing for its Main Board listing on the Hong Kong Stock Exchange on June 7, 2026. China International Capital Corporation (CICC) and China Merchants Securities (International) acted as joint sponsors. According to Frost & Sullivan, by 2025 sales volume, the company is the world’s largest provider of human tetanus antitoxin (TAT) with a 45.8% global market share; in China, its share stood at 65.8%, having remained above 50% for 19 consecutive years.

NewTimeSpace News: According to HKEX disclosures, Jiangxi Institute of Biological Products Inc. passed the Main Board listing hearing onJune 7, 2026, with CICC and China Merchants Securities (International) as joint sponsors.

Jiangxi Biology isChina’s largest manufacturer and exporter of human TAT. Per Frost & Sullivan data for 2025:By sales volume: Rankedfirst globally and in Chinafor human TAT, with market shares of 45.8% and 65.8% respectively; has held over 50% share in China for 19 straight years.2025 human TAT sales:29.9 million vials, exported to more than 30 countries and regions across Asia and Africa, accounting for nearly 100% of China’s total TAT exports.By revenue: Also rankedfirst globally and in Chinafor human TAT, with market shares of 33.2% and 66.9% respectively.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Jiangxi Biology IPO pass the listing hearing